HUTCHMED 提交 6-K，披露将举办 savolitinib 非小细胞肺癌近期临床数据专家交流活动
6-K - HUTCHMED (China) Ltd (0001648257) (Filer)
HUTCHMED (China) Limited 于 2026 年 10 月提交 Form 6-K，附件为公司将举办专家交流活动的新闻稿，主题是 savolitinib 在非小细胞肺癌中的近期临床数据。文件由首席财务官 Johnny Cheng 于 10 月 27 日签署。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
Exhibit 99.1 | | Press release relating to HUTCHMED to host expert insights event on recent savolitinib clinical data in non-small cell lung cancer |
| | |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: October 27, 2026
3
来源：SEC EDGAR · 本站存档